Keytruda Receives New Indication for Metastatic Small-Cell Lung Cancer After Disease Progression

August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights - FDA Approvals

On June 17, 2019, the FDA granted accelerated approval to pembrolizumab (Keytruda; Merck) monotherapy for the treatment of patients with metastatic small-cell lung cancer whose disease progressed during or after platinum-based chemotherapy and at least 1 previous therapy. The FDA granted this application a priority review, making it the fifth FDA approval this year for pembrolizumab.

This new indication was based on data from 83 patients with small-cell lung cancer whose disease progressed during or after ≥2 previous therapies and were enrolled in the multicenter, nonrandomized, open-label KEYNOTE-158 or KEYNOTE-028 clinical trials.

Treatment with pembrolizumab continued until disease progression, unacceptable toxicity, or a maximum of 24 months. Overall response rate (ORR) and duration of response were the primary end points.

The ORR was 19% (95% confidence interval, 11-29), including 2% complete responses and 17% partial responses. Of the 16 responding patients, 15 (94%) sustained a response for ≥6 months. The responses were durable for ≥12 months in 10 (63%) patients and for ≥18 months in 9 (56%) patients.

The safety profile in this study was similar to that seen in other studies with pembrolizumab monotherapy. A total of 9% of patients discontinued treatment because of adverse events, and 25% of the patients had at least 1 dose of pembrolizumab withheld because of an adverse reaction. Serious adverse events were reported in 31% of patients, most often (≥2%) pneumonia and pleural effusion.

Related Items
November 11, 2019 — Oncology News & Updates
Web Exclusives published on November 13, 2019 in Drug Updates, FDA Approvals, In the News
October 28, 2019 – Oncology News & Updates
Yvette Florio Lane
Web Exclusives published on October 28, 2019 in FDA Approvals, In the News
Vincristine, Racial Disparities in Multiple Myeloma, and HER2 Metastatic Breast Cancer Are in the News
Yvette Florio Lane
Web Exclusives published on October 22, 2019 in Breast Cancer, FDA Approvals, In the News, Multiple Myeloma, Pediatric Cancer
FDA Approves Darzalex Combination for First-Line Treatment of Transplant-Eligible Patients with Multiple Myeloma
Web Exclusives published on September 27, 2019 in FDA Approvals, Multiple Myeloma, In the News
Polivy FDA Approved for Patients with Relapsed or Refractory DLBCL
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights published on August 16, 2019 in FDA Approvals
Last modified: August 16, 2019
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME